Evgeny Arons, Hong Zhou, Mark Sokolsky, Daniel Gorelik, Katherine Potocka, Sarah Davies, Erin Fykes, Katherine Still, Daniel C Edelman, Yonghong Wang, Paul S Meltzer, Mark Raffeld, Adrian Wiestner, Liqiang Xi, Hao-Wei Wang, Maryalice Stetler-Stevenson, Constance Yuan, Robert J Kreitman
Hairy cell leukemia (HCL) is a purine analog-responsive B-cell malignancy containing the BRAF V600E mutation, expressing CD22, CD11c, CD103, tartrate resistant acid phosphatase (TRAP) CD25, CD123, and annexin 1A. BRAF V600E and the latter 4 markers are usually absent in the more aggressive and chemoresistant variant HCLv. To evaluate differences between HCL and HCLv, expression microarrays comparing HCL with HCLv were performed for 24694 genes using 47323 probes. Microarray data from 35 HCL and 27 HCLv purified samples showed the greatest HCL-HCLv difference in the muscle-associated gene MYF6, expressed by its 2 probes 18...
2020: PloS One